Differences in Expected Number of Clinical Management Events before and during Treatment with Sphingosine-1-Phosphate Receptor Modulators for Multiple Sclerosis
Background: Sphingosine-1-phosphate receptor modulators (S1Ps), a class of oral disease-modifying therapies (DMTs) for multiple sclerosis...
Adherence to Oral Disease Modifying Therapies in Clinical Practice and Patient-Centered Outcomes
Background: There are more than 20 disease modifying therapies (DMTs) approved for treatment of Multiple Sclerosis. Previous studies in the...
Health and Wellness Needs Reported to Influence Quality of Life in People with Relapsing-Remitting Multiple Sclerosis, a Qualitative Investigation
Background: Multiple sclerosis (MS) is a chronic progressive neurological disease diagnosed commonly between 20-50 years of age, with over...
Direct Cost Associated with Multiple Sclerosis and Important Components; A Population-Based Study 1997-2017
Direct cost associated with Multiple sclerosis: A Population-Based Study 1997-2017 Background: Multiple sclerosis (MS) is a chronic...
An Update on Participants in the Iconquerms Network.
Background: iConquerMS is a multiple sclerosis (MS) participant-powered research network (PPRN), dedicated to engaging people affected by...
Improving Health Outcomes of MS Patients during the Pandemic
Background: Living with MS has been particularly challenging during the pandemic; from the emotional and physical toll, to fears about...
Integrating User Experience Improves Participant Engagement: A Co-Design Initiative in the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Improvement Research Collaborative.
Background: MS-CQI is the first multi-center improvement research collaborative for MS care. MS-CQI was a three-year study (2018-2020) to...